Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

NCT02510950 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Glioblastoma Multiforme
Astrocytoma, Grade IV

Interventions

BIOLOGICAL: Personalized peptide vaccine
DRUG: Poly-ICLC
DRUG: Temozolomide

Sponsor

Washington University School of Medicine